Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with significant mortality and morbidity.
• Existing AF treatments have limitations in efficacy and present considerable side effects.
• Histone deacetylases (HDACs) are implicated in cardiovascular disease pathophysiology and AF development.

Purpose of the Study:

• To review the current understanding of HDACs and their inhibitors in the context of AF.
• To explore the potential of HDAC inhibition as a novel therapeutic approach for AF.
• To dissect the underlying molecular mechanisms through which HDACs influence AF.

Main Methods:

• Literature review of studies on HDACs, HDAC inhibitors, and atrial fibrillation.
• Analysis of the role of HDACs in cardiac electrophysiological and structural remodeling.
• Discussion of potential therapeutic strategies involving HDAC inhibition for AF.

Main Results:

• HDACs play a critical role in the development and progression of AF.
• HDAC inhibition demonstrates potential for modifying AF-related electrical and structural remodeling.
• Targeting HDACs could offer a novel upstream therapeutic strategy for AF.

Conclusions:

• HDAC inhibition represents a promising novel therapeutic avenue for managing atrial fibrillation.
• Further research into HDACs and their inhibitors is warranted to develop effective AF treatments.
• Understanding HDAC mechanisms is key to advancing AF therapy.